肝癌中的Glypican-3缺乏会调节MAPK/ERK通路,但会降低细胞增殖
Joon-Yong Chung1, Woonghee Lee1, Olivia W Lee2
1Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health Bethesda, MD 20892, USA.
American journal of cancer research
|August 8, 2024
概括
在肝癌细胞中的Glypican-3 (GPC3) 淘汰会减少瘤的增殖和生长. 这项研究开发了GPC3-Knockout模型,用于评估针对GPC3的疗法和成像剂.
科学领域:
- 肝细胞癌和肝母细胞瘤研究
- 癌症生物学和治疗目标识别.
- 分子瘤学和信号通路分析
背景情况:
- 在肝癌中,Glypican-3 (GPC3) 过度表达,是治疗标.
- 在肝癌中GPC3的生物学意义仍然不完全理解.
- 关于GPC3在内在表达肝癌细胞系中的作用的数据有限.
研究的目的:
- 开发和表征Glypican-3淘汰赛 (GPC3-KO) 肝癌细胞系.
- 研究GPC3缺乏对癌细胞瘤性质的生物学影响.
- 评估GPC3-KO模型用于GPC3向药物开发和成像.
主要方法:
- 已建立的GPC3-KO HepG2和 Hep3B肝癌细胞系使用CRISPR/Cas9.9.
- 在体外和体内 (小鼠异种移植) 评估了瘤原性质 (扩散,迁移,入侵).
- 通过RNAseq和西部斑点分析了信号通路;使用免疫PET成像评估了抗体-药物合物 (Zr-GC33) 向.
主要成果:
- 删除GPC3显著降低了肝癌细胞的增殖,迁移,入侵和瘤生长.
- RNAseq揭示了细胞周期,入侵和迁移基因的下调,包括AKT/NFκB/WNT通路;pMAPK/ERK1/2被上调.
- 89Zr-GC33免疫PET成像成功地将GPC3表达瘤与GPC3-KO瘤区分开来.
结论:
- 肝癌细胞系的GPC3-knockout表现出瘤性降低和改变的信号通路.
- 在GPC3-KO线路中对pMAPK/ERK1/2的升调表明了适应性反应.
- 开发的GPC3-KO模型和immunoPET成像显示了用于GPC3-向药物开发的实用性.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
MAPK Signaling Cascades
5.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.3K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


